Drugs / NWRD08
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06276101 | May 2024 → Feb 2025 | cervical intraepithelial neoplasia grade 2/3 | Newish Technology (Beijing) Co., Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07175662 | Nov 2025 → May 2027 expected | cervical intraepithelial neoplasia grade 2/3 | Newish Biotech (Wuxi) Co., Ltd. | Recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT05905354 | Mar 2022 → Jun 2024 | cervical intraepithelial neoplasia grade 2/3 | Newish Technology (Beijing) Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NWRD08 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06276101 ↗ |
| Modality | Vaccine | “HPV therapeutic DNA vaccine NWRD08” NCT05905354 ↗ |
| Route | Intramuscular | “intramuscularly injected with NWRD08” NCT05905354 ↗ |